DEF 14C: Mustang Bio Stockholders Approve Warrant Share Issuance to Comply with Nasdaq Listing Rules

Mustang Bio's majority stockholders approved the issuance of up to 5,475,082 common shares underlying outstanding warrants to comply with Nasdaq Listing Rule 5635(d).

Summary

• Mustang Bio is providing an information statement to its stockholders regarding the approval of a warrant share issuance.
• On February 19, 2025, the majority holders of Mustang Bio's common and Class A preferred stock approved the issuance of up to 5,475,082 shares of common stock underlying certain outstanding warrants.
• This issuance is related to a Securities Purchase Agreement dated February 5, 2025, and an engagement letter with H.C. Wainwright & Co., LLC dated October 23, 2024.
• The approval was obtained via written consent in lieu of a meeting.
• The company is issuing this statement to comply with Rule 14c-2 of the Securities Exchange Act of 1934 and Section 228 of the General Corporation Law of the State of Delaware.
• The warrant share issuance will become effective 20 days after the information statement is mailed, expected to be around March 23, 2025.
• The company received net proceeds of approximately $6.9 million from the offering related to these warrants, which will be used for working capital and general corporate purposes.
• The potential issuance of the warrant shares would result in substantial dilution for existing stockholders.
• The company is seeking stockholder approval to comply with Nasdaq Listing Rule 5635(d), which requires approval for issuances exceeding 20% of outstanding common stock.
• As of February 19, 2025, there were 1,910,131 shares of common stock, 845,385 shares of Class A common stock, and 250,000 shares of Class A preferred stock outstanding.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily conveying information about a required stockholder approval for a warrant issuance. While the dilution is a negative, the capital raised is a positive, balancing the sentiment.

Positives

• The company has secured $6.9 million in net proceeds from the offering, which will be used for working capital and general corporate purposes.
• The company is taking necessary steps to comply with Nasdaq Listing Rule 5635(d), ensuring continued listing on the Nasdaq Capital Market.

Negatives

• The potential issuance of the warrant shares will result in substantial dilution of existing stockholders' percentage ownership.
• The company incurred significant fees and expenses related to the offering, including cash fees, management fees, and legal expenses to the placement agent.

Risks

• The company cannot predict whether or when the warrant holders will exercise their warrants.
• The issuance of a significant number of shares could negatively impact the market price of the common stock.
• The company's business and financial performance are subject to substantial risks and uncertainties, and actual results could differ materially from forward-looking statements.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. The company cannot predict when or if the warrant holders will exercise their warrants.

Industry Context

Many small cap biotech companies need to raise capital to fund research and development. This type of warrant offering is a common way for these companies to raise capital, but it can be dilutive to existing shareholders.

Comparison to Industry Standards

• Warrant offerings are a common financing tool for small-cap biotech companies like Mustang Bio.
• Comparable companies such as Cellectis and bluebird bio have also utilized similar financing strategies involving warrants and equity offerings to fund their operations and research programs.
• The fees paid to the placement agent (7% cash fee and 1% management fee) are within the typical range for such transactions in the biotech industry.

Stakeholder Impact

• Existing stockholders will experience dilution of their percentage ownership if the warrant holders exercise their warrants.
• The company will have additional capital for working capital and general corporate purposes, potentially benefiting employees and other stakeholders.

Next Steps

• The Warrant Share Issuance will become effective 20 days after the Information Statement is mailed, expected to be around March 23, 2025.
• The company will monitor the exercise of warrants by the holders.

Key Dates

Keywords

Warrant Share Issuance, Nasdaq Listing Rule 5635(d), Common Stock, Stockholder Approval, Mustang Bio, Warrants, Dilution, Offering